Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14916471 | 0.79 | ALDH1A1 (0.54) | ALDH1A1GAANPC1KMT2AMEN1 | |
| SCHEMBL10895693 | 0.73 | KMT2A (0.44) | ALDH1A1GAANPC1KMT2ATDP1 | |
| SCHEMBL10896122 | 0.73 | TSHR (0.45) | ALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL14113763 | 0.70 | ALDH1A1 (0.38) | ALDH1A1GAANPC1KMT2ATDP1 | |
| SCHEMBL5395538 | 0.68 | ALDH1A1 (0.50) | ALDH1A1GAANPC1KMT2ATDP1 | |
| SCHEMBL21144646 | 0.68 | PIN1 (0.54) | ALDH1A1 | |
| SCHEMBL5387895 | 0.68 | ALDH1A1 (0.50) | ALDH1A1GAANPC1KMT2ATDP1 | |
| SCHEMBL22779306 | 0.66 | ALDH1A1 (0.36) | ALDH1A1GAANPC1KMT2ATDP1 | |
| SCHEMBL9565814 | 0.66 | ALDH1A1 (0.40) | ALDH1A1GAANPC1KMT2ATDP1 | |
| SCHEMBL22952568 | 0.66 | ALDH1A1 (0.36) | ALDH1A1GAANPC1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010039275-A1 | Use of 2,4-diaminothiazole derivatives | NOVO NORDISK A/S (DK) | 2001-11-08 | — | — | US | disclosed |
| WO-2001056567-A1 | 2,4-DIAMINOTHIAZOLE DERIVATIVES AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 (GSK-3) INHIBITORS | NOVO NORDISK A/S (DK) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039275-A1 | Use of 2,4-diaminothiazole derivatives | GSK3A, GSK3B, GSKIP | ALDH1A1 976/4885GAA 170/4885NPC1 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.